The Pandemic Institute, in collaboration with The National Institute for Health and Care Research (NIHR) Health Protection Research Unit in Emerging and Zoonotic Infections (HPRU EZI), are pleased to announce recently awarded funding aimed at tackling the growing threat of emerging infectious diseases. Over £400k has been awarded for research into Oropouche (OROV) and Mpox (MPXV) viruses, both of which pose significant global health risks.

The research will focus on understanding the complexities of these emerging infections, with particular attention given to how they spread, how the immune system responds, and potential interventions such as diagnostics, treatments, and vaccines.

Oropouche Funding

Oropouche is transmitted to humans primarily through midge or mosquito bites. While there is currently no evidence of human-to-human transmission, the virus has been responsible for large outbreaks across South America, particularly in Brazil, Bolivia, Colombia, Peru, and Cuba. Recent imported cases have also been reported in Spain, Italy, Germany, and the United States. Oropouche typically causes a flu-like illness, with symptoms including rashes, headaches, and joint or muscle pain. More severe cases have been linked to birth defects.

The funded research projects will explore key areas of Oropouche virus, including:

• Development of rapid diagnostic tests
• Design and development of vaccines against Oropouche virus
• The risk of the disease being spread in the UK by different midge and mosquito species
• Understanding of public perceptions of the virus to develop effective public health messaging
• The risk of different variants of the virus to unborn children

Mpox Funding

Mpox, caused by the monkeypox virus (MPXV), continues to pose a global health challenge. The outbreak of Clade II Mpox, which began in 2022, has drawn significant attention due to its widespread impact. In August 2024, an upsurge in cases across Africa caused by the more deadly Clade I variation of the virus resulted in The World Health Organization (WHO) declaring the situation a public health emergency of international concern (PHEIC). In response, The Pandemic Institute has awarded funding focusing on several key areas, including:

• Research exploring the potential for airborne transmission of Mpox
• How the immune system of vaccinated and previously infected people responds to new infections
• Development of a rapid low-cost sensor for Mpox diagnostics
• Working in partnership with communities to co-create health messaging

Professor Tom Solomon CBE, Director of The Pandemic Institute, said:

“The funding provided for Oropouche and Mpox research is crucial as we continue to face new and evolving infectious disease threats. This initiative will support the development of vital tools to prevent and control these diseases, ultimately saving lives and improving global health outcomes.”

This funding initiative underscores The Pandemic Institute’s commitment to addressing emerging infectious diseases through rapidly mobilising funds for collaborative research. For more information on our funding schemes, visit our funding pages.